|Bid||0.00 x 900|
|Ask||0.00 x 900|
|Day's Range||37.62 - 37.92|
|52 Week Range||24.54 - 37.92|
|PE Ratio (TTM)||99.66|
|Earnings Date||Oct 24, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||39.32|
SAN DIEGO and MARLBOROUGH, Mass., Sept. 22, 2018 /PRNewswire/ -- Today, Boston Scientific (BSX) announced positive 12-month data from the IMPERIAL trial, the first head-to-head drug-eluting stent trial in the superficial femoral artery (SFA). Results were presented during a late-breaking clinical trial session at the 30th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, in San Diego, and at the annual Cardiovascular and Interventional Radiological Society of Europe (CIRSE) congress in Lisbon, Portugal. The clinical findings will be published in The Lancet.
RESEARCH REPORTS These reports, excerpted and edited by Barron’s, were issued recently by investment and research firms. The reports are a sampling of analysts’ thinking; they should not be considered the views or recommendations of Barron’s.
On September 19, Abbott Laboratories (ABT) was trading at a forward PE multiple of 21.8x, while its trailing-12-month PE multiple was 52.4x. Its forward PE and trailing-12-month PE multiples were 19.2x and 55.7x, respectively, a few months ago in May.
MARLBOROUGH, Mass., Sept. 21, 2018 /PRNewswire/ -- Boston Scientific Corporation (BSX) today announced the global launch of the LithoVue Empower™ Retrieval Deployment Device, designed to be used with the LithoVue™ Single-Use Digital Flexible Ureteroscope and compatible nitinol retrieval basket to enable urologists to operate a ureteroscope and basket simultaneously when retrieving kidney stones via flexible ureteroscopy (URS).
As of September 19, Abbott Laboratories (ABT) has registered a rise of ~17% YTD (year-to-date). In the same period, the S&P 500 has risen ~8%. Abbott Laboratories has clearly surpassed the market’s returns so far in 2018.
On September 18, Abbott Laboratories (ABT) ended the trading day at $68.41, up ~1.1% from its previous trading day’s closing price. The stock has maintained growth momentum over the last year.
Abbott Laboratories (ABT) is one of the leading medical technology companies in the world. It offers products across its Medical Devices, Nutrition, Diagnostics, and Established Pharmaceuticals segments, with most of its products having the highest market shares in their respective markets. On July 18, the company released its most recent quarterly results and exceeded analysts’ estimates.
Hologic (HOLX) is a medical technology company focused on women’s health with headquarters in Marlborough, Massachusetts. The company offers solutions across four segments including diagnostics, breast and skeletal health, gynecological surgery, and medical aesthetics. The company recently provided an update on the financial impact of its recently announced marketing and distribution suspension of its TempSure Vitalia handpiece and probes. We discussed the details in the previous article of this series. ...
On September 4, Jefferies (JEF) upgraded its recommendation on Boston Scientific (BSX) from “hold” to “buy.” The brokerage has a target price of $42 on Boston Scientific. Needham also raised its target price on Boston Scientific on September 7. This shows that the Wall Street is increasingly confident about Boston Scientific’s growth prospects.
Boston Scientific (BSX) stock traded at its 14-year high on September 13. The company has been witnessing a bull run over the last year, driven by its strong financial performance, launches, approvals, and a strong inorganic growth strategy.
MARLBOROUGH, Mass. , Sept. 17, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced key data that will be presented at the 30th Transcatheter Cardiovascular Therapeutics (TCT), ...
Boston Scientific (BSX) has been executing on its inorganic growth strategy in 2018. The company has announced nine acquisitions year-to-date, with the latest acquisition announced on September 6. On that date, Boston Scientific announced that it entered into an agreement to acquire Augmenix for an upfront payment of $500 million and additional sales-based milestone payments of up to $100 million.
On September 14, Boston Scientific (BSX) was trading at a forward PE (price-to-earnings) ratio of 24.4x, compared to the industry’s average PE ratio of 22.4x. Boston Scientific’s forward EV-to-EBITDA multiple is 19.1x, which is higher than the industry average of 16.7x. On September 14, Boston Scientific’s peers Abbott Laboratories (ABT), Edwards Lifesciences (EW), and Medtronic (MDT) had forward PE multiples of 21.7x, 28.4x, and 18.3x, respectively.
BSX stock is trading ~53.0% higher than its 52-week low of $24.54 reported on December 6, 2017. Over the last week, BSX stock has risen ~4.5%. BSX stock has risen ~11.6% over the last month. Year-to-date, BSX stock has reported stellar gains of ~52.0%.
Bullish options traders have racked up huge profits in Boston Scientific Corp. On August 15, Investitute's tracking systems detected the purchase of 4,500 September $36 calls in one print for $0.21 with shares at $33.89.
“Markets today are moving primarily on China trade [and] tariff news,” according to Mark Esposito, chief executive of Esposito Securities in Dallas. Boston Scientific's stock jumped 3.24% Thursday, to close the day at $37.62. The stock recorded a trading volume of 14,332,530 shares, which was above its three months average volume of 6,591,750 shares.
Currently, BSX stock is trading near its all-time high. Boston Scientific (BSX) stock has been on a bullish trend over the last year, driven by strong fundamentals, a robust acquisition strategy, and a diverse product pipeline. Why did BSX stock jump today?
Today, Zimmer Biomet Holdings (ZBH) is trading at $128.82, which represents a ~2.08% rise from yesterday’s close of $126.19.
In the second quarter, Boston Scientific’s (BSX) peripheral interventions (or PI) business reported revenue of nearly $304 million, a YoY (year-over-year) rise of ~8.7%. The anticipated launches of Eluvia and Ranger systems in the United States in 2019 and 2020, respectively, are expected to further boost the company’s PI sales in the coming years. In the second quarter, Boston Scientific’s interventional cardiology (or IC) business, which includes the coronary therapies and structural heart businesses, reported revenue of close to $662 million, a YoY rise of ~7.6%.
Boston Scientific (BSX) aims to increase the adoption of its HeartLogic Heart Failure technology by demonstrating the quantitative benefits of proactively managing probable heart failure patients. The above diagram shows how HeartLogic is focused on increasing its market share by improving the quality of care for heart failure patients. The company is also witnessing the increased adoption of the EMBLEM MRI-compliant Subcutaneous Implantable Defibrillator (or S-ICD) due to enhancements that have made it easier and less time-consuming to implant them as well as due to the inclusion of ICDs in the clinical guidelines provided by cardiology societies such as American Hospital Association, the American College of Cardiology, and the Heart Rhythm Society (HRM).